Chris Meredith and Pierre Chauvineau bring a wealth of experience to the growing business
Creavo Medical Technologies (Creavo), the UK-based medical device company has appointed senior medical technology industry leaders Chris Meredith and Pierre Chauvineau as non-executive directors.
The new members of the company’s expanded board will provide ongoing guidance and governance as Creavo continues to work towards full commercialisation of its portable magnetocardiography (MCG) device.
Chris Meredith is currently Group Chief Executive Officer of Advanced Medical Solutions Group plc and has previously held senior sales and marketing roles at Smiths Industries – now Smiths Group plc, Cardinal Health, Banner Pharmacaps, and Aster Cephac. His experience covers contract manufacturing, product development, clinical research and branded product sales, all within the medical device, pharmaceutical or consumer healthcare markets.
Pierre Chauvineau has over 25 years’ international business leadership experience in corporate and start-up companies within the medical technology industry. He recently held the role of Vice President and General Manager Rhythm Management Europe at medical device manufacturer Boston Scientific. He was also Vice President and General Manager International for Cameron Health, a medical technology business – later acquired by Boston Scientific – which developed a novel cardiac defibrillator. He has also held a variety of senior roles in the cardiac rhythm management division of medical technology firm Medtronic.
Robert Barr, Chairman of Creavo commented “We are delighted to welcome both Chris and Pierre to the board at this important time as we move towards full commercialisation. Their complementary skills and experience in developing world class medical device businesses and launching disruptive technologies in the cardiology space will add significant value as we move into the next phase of Creavo’s evolution.”
In emergency medicine, Creavo’s technology is designed to meet an urgent clinical need, to help physicians quickly rule out serious heart-related problems at the point of admission to emergency departments. Identifying these patients early reduces patient anxiety and can save the hospitals valuable time, resources and bed space. Financially, the device has the potential to save the UK healthcare system alone up to £200 million a year.
Following initial funding, the company raised £13.4m ($17m) in private equity funding in July 2017 for its MCG device. The round was oversubscribed and exceeded Creavo’s funding target, reflecting strong investor support and endorsement of the company’s strategy and team.